Cross Posted
Heads up! New kinase inhibitor targeting BCR-ABL - Dr. S. Nimer on the is
part of the development team.....
Cheers,
Cheryl-Anne
Dr. Jerome Groopman Chairs Onconova Therapeutics Inc. New Clinical Advisory
Board
BIOWIRE2K
PRINCETON, N.J.--(BUSINESS WIRE)--March 23, 2005--
Board to Advise Development Team that Spearheaded Recent
Publications on Discovery of Novel Kinase Inhibitors in Two Leading Journals
Onconova Therapeutics, Inc., a privately-held company focused on cancer
therapy, announced today the creation of its Clinical Advisory Board (CAB),
chaired by Dr. Jerome E. Groopman, and the appointment of its first five
members. Onconova's CAB members are distinguished oncologists from leading
medical centers in the U.S. and will advise the company in clinical and
regulatory strategies, particularly for the ongoing development of the
Company's lead anticancer agent ON 01910.Na. This novel non-ATP competitive
kinase inhibitor selectively blocks several important targets in cancer. The
drug candidate entered Phase I clinical trials at the Johns Hopkins Kimmel
Cancer Center, Baltimore, MD in July 2004. The CAB met for the first time
this month in New York.
Two Onconova kinase inhibitors have been the subject of papers published in
early 2005. ON 01910.Na was the subject of a peer-reviewed paper titled "ON
01910, a non-ATP-competitive small molecule inhibitor of PLK1, is a potent
anticancer agent," which appeared in the journal Cancer Cell in March (Vol
7, 275-286, March 2005). The company's advanced preclinical stage compound
targeting BCR-ABL, involved in Chronic Myelogenous Leukemia (CML), was
featured in the Proceedings of the National Academy of Sciences in February
(PNAS February 8, 2005, vol. 102, no. 6, pp 1992-1997)
Onconova's Clinical Advisory Board is chaired by Dr. Jerome E. Groopman, who
holds the Dina and Raphael Recanati Chair of Medicine at the Harvard Medical
School and is Chief of Experimental Medicine at the Beth Israel Deaconess
Medical Center. Dr. Groopman was Chairman of the Advisory Committee to the
FDA for Biological Response Modifiers. His research has focused on cancer
and AIDS. He is also a writer for The New Yorker, and has written three
popular books, most recently "The Anatomy of Hope". Other founding members
of the CAB are Dr. James F. Holland, Dr. Ross C. Donehower, Dr. Stephen D.
Nimer, and Dr. William N. Hait.
-- Dr. James F. Holland, Distinguished Professor of Neoplastic Diseases at
Mount Sinai Medical Center, NY, received the prestigious Lasker Award in
1972 for his work in cancer chemotherapy. Dr. Holland has been working
closely with Onconova on developing preclinical models for testing
ON01910.Na.
-- Dr. Ross C. Donehower, Ludwig Professor in Clinical Investigation of
Cancer, is Director of the Division of Medical Oncology at the Johns Hopkins
Kimmel Cancer Center and is an expert in the pharmacology of
chemotherapeutic drugs.
-- Dr. Stephen D. Nimer is the Head of the Division of Hematologic Oncology
and Chief of the Hematology Service, Memorial Sloan Kettering Cancer Center,
NY. Dr. Nimer received one of two awards given to U.S. investigators by The
Leukemia & Lymphoma Society as a Specialized Center of Research Excellence
in myeloid malignancies.
-- Dr. William N. Hait, Director of The Cancer Institute of New Jersey and
Professor of Medicine and Pharmacology, UMDNJ/Robert Wood Johnson Medical
School, NJ, is an expert in breast cancer and is conducting basic research
in signal transduction systems altered in malignancy.
"All of us on the Advisory Board are looking forward to marshalling our
energy and expertise to the development of the PLK1 inhibitor (ON 01910.Na)
as a novel anti-cancer therapy," said Dr. Groopman.
ON 01910.Na is the first in a new class of non-ATP competitive kinase
inhibitors being developed by Onconova that discriminate between cancerous
and normal cells by targeting specific checkpoints in the cell cycle. In
pre-clinical animal studies, ON 01910.Na was active against most tumor
types, including those resistant to standard chemotherapy, and did not
exhibit common toxic effects of chemotherapy such as anemia or weight loss.
The Clinical Advisory Board will also advise Onconova on other drug
candidates being developed by the Company. These include ON 01210,
Ex-RAD(TM), for protection from whole-body radiation, being developed in
partnership with the Armed Forces Radiobiology Research Institute (AFRRI);
an advanced preclinical stage compound targeting BCR-ABL involved in Chronic
Myelogenous Leukemia (CML). A key attribute of this inhibitor is its potent
activity against all mutant forms of BCR-ABL kinase found in drug-resistant
CML. The Company also has a strong pipeline of specific enzyme inhibitors,
applicable for cancer, autoimmune, ophthalmic, and central nervous system
indications, in earlier stages of development.
About Onconova
Onconova Therapeutics, Inc. discovers and develops small molecule, patent
protected drugs that employ novel approaches to combating cancer and other
diseases. To date, nearly 20 U.S. patents have been issued. In addition to
the development stage compounds described above, the Company has a strong
pipeline of specific enzyme inhibitors, applicable for cancer, autoimmune,
ophthalmic, and central nervous system indications, in earlier stages of
development.
For additional information on Onconova Therapeutics Inc., visit the
company's website at <http://www.onconova.com/